Theranexus
Developing drug combinations that consist of one compound that targets neurons and another that modulates the activity of astrocytes.
Launch date
Employees
Market cap
€4.6m
Enterprise valuation
€3m (Public information from Sep 2024)
Share price
€0.59 ALTHX.PA
Company register number 791889777
Lyon Auvergne-Rhône-Alpes (HQ)
Financials
Estimates*
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| EBITDA | (7.4m) | (5.5m) | (8.7m) | (6.1m) | (7.3m) | (6.9m) | (6.9m) |
| Profit | (5.6m) | (4.8m) | (8.2m) | (6.6m) | (6.8m) | (7.3m) | (7.1m) |
| EV / EBITDA | -0.6x | -11.6x | -1.8x | -0.8x | -1.0x | -2.8x | -3.8x |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
€3.6m | Seed | ||
* | N/A | €20.4m Valuation: €48.4m | IPO |
| N/A | €2.2m | Post IPO Equity | |
* | N/A | Early VC | |
| Total Funding | €3.6m | ||
Related Content
Recent News about Theranexus
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.